Treace Medical Concepts, Inc. Cost of Revenue
Treace Medical Concepts, Inc. (TMCI) reported Cost of Revenue of $9.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-07
- Treace Medical Concepts, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $9.77M, a 1.39% increase year-over-year.
- Treace Medical Concepts, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $9.79M, a 8.30% decline year-over-year.
- Treace Medical Concepts, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $12.12M, a 8.41% decline year-over-year.
- Treace Medical Concepts, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $10.51M, a 17.36% increase year-over-year.
- Treace Medical Concepts, Inc. cost of goods and services sold for fiscal 2025 was $42.94M, a 4.49% increase from fiscal 2024.
- Treace Medical Concepts, Inc. cost of goods and services sold for fiscal 2024 was $41.09M, a 16.80% increase from fiscal 2023.
- Treace Medical Concepts, Inc. cost of goods and services sold for fiscal 2023 was $35.18M, a 37.79% increase from fiscal 2022.
- Treace Medical Concepts, Inc. cost of goods and services sold for fiscal 2022 was $25.53M, a 51.18% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.77M 10-Q · filed 2026-08-07 | $19.56M 10-Q · filed 2026-08-07 | $31.68M derived: sum of 3 quarters · filed 2026-08-07 | $42.19M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $9.79M 10-Q · filed 2026-05-08 | $21.91M derived: sum of 2 quarters · filed 2026-05-08 | $32.42M derived: sum of 3 quarters · filed 2026-05-08 | $42.05M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $12.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $22.63M derived: sum of 2 quarters · filed 2026-02-27 | $32.26M derived: sum of 3 quarters · filed 2026-08-07 | $42.94M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $10.51M 10-Q · filed 2025-11-06 | $20.14M derived: sum of 2 quarters · filed 2026-08-07 | $30.82M 10-Q · filed 2025-11-06 | $44.05M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $9.63M 10-Q · filed 2026-08-07 | $20.31M 10-Q · filed 2026-08-07 | $33.54M derived: sum of 3 quarters · filed 2026-08-07 | $42.50M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $10.68M 10-Q · filed 2026-05-08 | $23.91M derived: sum of 2 quarters · filed 2026-05-08 | $32.86M derived: sum of 3 quarters · filed 2026-05-08 | $41.64M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $13.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $22.18M derived: sum of 2 quarters · filed 2026-02-27 | $30.97M derived: sum of 3 quarters · filed 2026-02-27 | $41.09M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $8.95M 10-Q · filed 2025-11-06 | $17.73M derived: sum of 2 quarters · filed 2025-11-06 | $27.86M 10-Q · filed 2025-11-06 | $39.33M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $8.78M 10-Q · filed 2025-08-07 | $18.91M 10-Q · filed 2025-08-07 | $30.38M derived: sum of 3 quarters · filed 2026-02-27 | $38.38M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $10.13M 10-Q · filed 2025-05-08 | $21.60M derived: sum of 2 quarters · filed 2026-02-27 | $29.59M derived: sum of 3 quarters · filed 2026-02-27 | $37.27M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $11.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $19.47M derived: sum of 2 quarters · filed 2026-02-27 | $27.14M derived: sum of 3 quarters · filed 2026-02-27 | $35.18M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $8.00M 10-Q · filed 2024-11-05 | $15.67M derived: sum of 2 quarters · filed 2024-11-05 | $23.71M 10-Q · filed 2024-11-05 | $32.73M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $7.67M 10-Q · filed 2024-08-06 | $15.71M 10-Q · filed 2024-08-06 | $24.73M derived: sum of 3 quarters · filed 2025-02-27 | $30.82M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $8.04M 10-Q · filed 2024-05-07 | $17.06M derived: sum of 2 quarters · filed 2025-02-27 | $23.15M derived: sum of 3 quarters · filed 2025-02-27 | $28.44M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $15.11M derived: sum of 2 quarters · filed 2025-02-27 | $20.40M derived: sum of 3 quarters · filed 2025-02-27 | $25.53M 10-K · filed 2025-02-27 | $27.52M 10-K · filed 2023-03-08 | |||
| 2022-09-30 | $6.09M 10-Q · filed 2023-11-09 | $6.62M 10-Q · filed 2022-11-09 | $11.38M derived: sum of 2 quarters · filed 2023-11-09 | $16.51M 10-Q · filed 2023-11-09 | $17.78M 10-Q · filed 2022-11-09 | $21.88M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $5.29M 10-Q · filed 2023-08-09 | $5.65M 10-Q · filed 2022-08-10 | $10.42M 10-Q · filed 2023-08-09 | $11.16M 10-Q · filed 2022-08-10 | $15.79M derived: sum of 3 quarters · filed 2024-02-27 | $20.04M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | $5.13M 10-Q · filed 2023-05-09 | $5.51M 10-Q · filed 2022-05-06 | $10.50M derived: sum of 2 quarters · filed 2024-02-27 | $14.75M derived: sum of 3 quarters · filed 2024-02-27 | $18.69M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $9.62M derived: sum of 2 quarters · filed 2024-02-27 | $13.56M derived: sum of 3 quarters · filed 2024-02-27 | $16.89M 10-K · filed 2024-02-27 | $17.83M 10-K · filed 2022-03-04 | |||
| 2021-09-30 | $4.25M 10-Q · filed 2022-11-09 | $8.19M derived: sum of 2 quarters · filed 2022-11-09 | $11.52M 10-Q · filed 2022-11-09 | $16.60M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2021-06-30 | $3.94M 10-Q · filed 2022-08-10 | $7.27M 10-Q · filed 2022-08-10 | $12.36M derived: sum of 3 quarters · filed 2023-03-08 | $15.27M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2021-03-31 | $3.33M 10-Q · filed 2022-05-06 | $8.41M derived: sum of 2 quarters · filed 2023-03-08 | $11.32M derived: sum of 3 quarters · filed 2023-03-08 | $13.41M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2020-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $8.00M derived: sum of 2 quarters · filed 2023-03-08 | $10.08M derived: sum of 3 quarters · filed 2023-03-08 | $12.47M 10-K · filed 2023-03-08 | ||||
| 2020-09-30 | $2.91M 10-Q · filed 2021-11-04 | $5.00M derived: sum of 2 quarters · filed 2021-11-04 | $7.39M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $2.08M 10-Q · filed 2021-08-05 | $4.47M 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $2.39M 10-Q · filed 2021-05-25 | |||||||
| 2019-12-31 | $7.63M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |